Status:
RECRUITING
International Multicentric Study ARON-1
Lead Sponsor:
Hospital of Macerata
Conditions:
Metastatic Renal Cell Carcinoma (mRCC)
Eligibility:
All Genders
18+ years
Brief Summary
The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC. Two Supplementary ...
Eligibility Criteria
Inclusion
- Patients aged \>18y
- Cytological or Histologically confirmed diagnosis of clear cell or non-clear cell RCC
- Histologically or radiologically confirmed diagnosis of metastatic disease
- First-line treatment with nivolumab plus ipilimumab or nivolumab plus cabozantinib or pembrolizumab plus axitinib or pembrolizumab plus lenvatinib or avelumab plus axitinib or atezolizumab plus bevacizumab
Exclusion
- Patients without histologically confirmed diagnosis of RCC
- Patients without histologically or radiologically confirmed metastatic disease
- Patients treated with immuno-combinations not included in the list reported in the Inclusion Criteria Section
Key Trial Info
Start Date :
March 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2027
Estimated Enrollment :
1220 Patients enrolled
Trial Details
Trial ID
NCT05287464
Start Date
March 10 2022
End Date
September 30 2027
Last Update
November 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ospedale di Macerata, UOC Oncologia
Macerata, Macerata, Italy, 62100